Biofarm Past Earnings Performance
Past criteria checks 4/6
Biofarm has been growing earnings at an average annual rate of 12.9%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 10.4% per year. Biofarm's return on equity is 17.7%, and it has net margins of 27.5%.
Key information
12.9%
Earnings growth rate
12.3%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 10.4% |
Return on equity | 17.7% |
Net Margin | 27.5% |
Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Mar 18Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?
Feb 18Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return
Jan 23A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)
Dec 25Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?
Dec 03Revenue & Expenses BreakdownBeta
How Biofarm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 280 | 77 | 110 | 0 |
30 Sep 23 | 297 | 75 | 117 | 0 |
30 Jun 23 | 301 | 77 | 116 | 0 |
31 Mar 23 | 297 | 76 | 112 | 0 |
31 Dec 22 | 277 | 71 | 106 | 0 |
30 Sep 22 | 269 | 71 | 101 | 0 |
30 Jun 22 | 260 | 68 | 98 | 0 |
31 Mar 22 | 253 | 65 | 94 | 0 |
31 Dec 21 | 239 | 60 | 90 | 0 |
30 Sep 21 | 241 | 64 | 90 | 0 |
30 Jun 21 | 231 | 61 | 86 | 0 |
31 Mar 21 | 215 | 58 | 80 | 0 |
31 Dec 20 | 216 | 54 | 82 | 0 |
30 Sep 20 | 214 | 56 | 80 | 0 |
30 Jun 20 | 205 | 52 | 81 | 0 |
31 Mar 20 | 211 | 53 | 88 | 0 |
31 Dec 19 | 195 | 51 | 75 | 0 |
30 Sep 19 | 189 | 42 | 88 | 0 |
30 Jun 19 | 195 | 44 | 64 | 0 |
31 Mar 19 | 189 | 43 | 65 | 0 |
31 Dec 18 | 184 | 38 | 64 | 0 |
30 Sep 18 | 179 | 43 | 61 | 0 |
30 Jun 18 | 171 | 38 | 64 | 0 |
31 Mar 18 | 176 | 39 | 59 | 0 |
31 Dec 17 | 170 | 36 | 58 | 0 |
30 Sep 17 | 167 | 35 | 53 | 0 |
30 Jun 17 | 165 | 35 | 55 | 0 |
31 Mar 17 | 155 | 32 | 52 | 0 |
31 Dec 16 | 152 | 29 | 52 | 0 |
30 Sep 16 | 149 | 29 | 45 | 0 |
30 Jun 16 | 148 | 27 | 58 | 0 |
31 Mar 16 | 138 | 20 | 44 | 0 |
31 Dec 15 | 149 | 27 | 44 | 0 |
30 Sep 15 | 147 | 27 | 48 | 0 |
30 Jun 15 | 138 | 27 | 34 | 0 |
31 Mar 15 | 138 | 30 | 47 | 0 |
31 Dec 14 | 129 | 27 | 46 | 0 |
30 Sep 14 | 122 | 28 | 43 | 0 |
30 Jun 14 | 120 | 27 | 54 | 0 |
31 Mar 14 | 121 | 27 | 43 | 0 |
31 Dec 13 | 118 | 26 | 43 | 0 |
30 Sep 13 | 113 | 22 | 52 | 0 |
30 Jun 13 | 110 | 22 | 40 | 0 |
Quality Earnings: BIO has high quality earnings.
Growing Profit Margin: BIO's current net profit margins (27.5%) are higher than last year (25.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIO's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: BIO's earnings growth over the past year (8.6%) is below its 5-year average (12.9% per year).
Earnings vs Industry: BIO earnings growth over the past year (8.6%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: BIO's Return on Equity (17.7%) is considered low.